How my gammy knee op could save the NHS millions: RICHARD LITTLEJOHN

Richard Littlejohn, the British journalist known for his sharp wit and often controversial opinions, revealed in a recent column that he had undergone a groundbreaking treatment for his chronic knee condition, potentially offering a solution that could significantly reduce the burden on the National Health Service (NHS). The treatment, known as Arthrosamid, is a gel-based therapy initially developed for horses and later adapted for human use. Littlejohn explained that he had been suffering from a debilitating knee condition for several years, which worsened during the pandemic. His symptoms resurfaced dramatically during a recent trip to the United States, where he attended the World Cup. After a long flight from Heathrow, he found himself unable to walk due to severe knee pain, likening his ordeal to that of the famed aviator Douglas Bader. This led him to seek a more permanent solution, especially after years of managing his condition through exercise and steroid injections, which proved increasingly ineffective. The turning point came when Littlejohn learned about a new treatment option. A friend, an American in his 70s, had undergone the procedure and returned to an active lifestyle within weeks. Inspired, Littlejohn contacted his consultant, Dr. Tim Waters, a specialist in hip and knee treatments at Spire Elstree. Dr. Waters informed him that the gel, Arthrosamid, was now available for human use and could be administered via a minimally invasive procedure involving six small injections. Littlejohn underwent the treatment on Tuesday, describing the process as quick and straightforward. He noted that the procedure took approximately 15 minutes under local anesthesia, with additional time for pre-operative preparations. Upon waking, he was surprised to find himself free of pain for the first time in six years. His cognitive function improved almost immediately, and he regained full mobility overnight. Dr. Waters predicted that Littlejohn would be back at the gym by Friday, a claim that seemed to come true. While the personal benefits were clear, Littlejohn highlighted the broader implications of the treatment for the NHS. Currently, over 110,000 knee replacement surgeries are conducted annually in the UK, each carrying substantial costs. Arthrosamid, which is available in Canada and across Europe, has already been used by 15,000 patients. Despite its availability elsewhere, the treatment remains inaccessible on the NHS, with a private cost of £2,700. Littlejohn expressed frustration over the delay in NHS approval, noting that while health officials often support costly new procedures, they frequently overlook basic healthcare needs. He argued that adopting Arthrosamid could lead to significant savings by reducing the number of knee replacements required, thus alleviating pressure on the NHS's resources. The treatment's success underscores a growing trend in alternative therapies for chronic conditions, particularly those affecting mobility. As more individuals explore non-surgical options, the demand for innovative treatments like Arthrosamid may increase, prompting further discussion on their integration into public healthcare systems. For now, Littlejohn's experience serves as a compelling example of how such advancements can transform individual lives and potentially reshape healthcare policies.